Autosomal Dominant Hypocalcemia (ADH)
3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BridgeBio PharmaCA - Palo Alto
2 programs1
1
EncaleretPhase 32 trials
EncaleretPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
BridgeBio PharmaEncaleret
BridgeBio PharmaEncaleret
BridgeBio PharmaEncaleret
TakedaNPSP795
Clinical Trials (4)
Total enrollment: 100 patients across 4 trials
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Start: Jan 2023Est. completion: Aug 202967 patients
Phase 3Active Not Recruiting
PTH-independent Effects of Encaleret
Start: Sep 2023Est. completion: Aug 202513 patients
Phase 2Completed
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
Start: Sep 2020Est. completion: Sep 202313 patients
Phase 2Completed
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Start: Jul 2014Est. completion: May 20157 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space